在患有中风后认知障碍的患者中,idebenone片的有效性和安全性:一项真实世界的研究
Yanqi Shao1, Xinyu Zhao2, Zunchun Xie3
1Department of Neurology, Zhejiang Provincial People's Hospital, Hangzhou, China.
Frontiers in neurology
|November 5, 2025
概括
伊德本片在三个月内显著改善了中风后患者的认知功能. 在这项现实研究中,该疗法表现出高度的坚持性和出色的安全性.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 脑卒中后认知障碍 (PSCI) 是中风的常见和使人虚弱的后果.
- 对PSCI的有效治疗对于改善患者的治疗结果和生活质量至关重要.
研究的目的:
- 评估在PSCI患者中idebenone的实际有效性,安全性和坚持性.
- 通过MoCA和MMSE评估idebenone对认知功能的影响.
主要方法:
- 一个单臂,多中心,现实世界的观测研究.
- 3,755名患有PSCI的患者接受了idebenone (30 mg三次每天) 治疗3个月.
- 通过MoCA和MMSE在基线和每月间隔评估认知功能.
主要成果:
- 在第3个月 (p < 0.001) 观察到MoCA和MMSE得分的显著改善.
- 三个月后,总有效率达到37.4-38.2%.
- 报告了高的药物坚持率 (96.9%) 和良好的安全性概况,轻度不良事件<2%.
结论:
- 三个月的idebenone疗法在PSCI患者的认知功能改善方面表现有前途.
- 在现实环境中,Idebenone表现出卓越的安全性和粘附性.
- 建议进行进一步的随机对照试验,以确认疗效和优化治疗.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
535
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
535
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801
Pharmacodynamics in Geriatric Patients: Effects of Age
182
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
182
Bioavailability Study Design: Healthy Subjects Versus Patients
140
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
140


